ArticleEcancermedicalscience2023

Re-challenge of immune checkpoint inhibitor pembrolizumab with concurrent tocilizumab after prior grade 3 pneumonitis.

Chitrakshi Nagpal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.